International Paper Reports Third Quarter 2026 Results

International Paper reported Q3 2026 net sales of $6.197 billion, down from $6.222 billion a year earlier, and a $1.097 billion loss from continuing operations that included a $1.377 billion non-cash goodwill impairment for its Packaging Solutions EMEA segment. Adjusted EBITDA was $843 million versus $859 million a year ago, while North America segment operating profit improved to $427 million from $204 million in Q2; free cash flow was negative $267 million. The company forecast FY 2026 North America operating profit of $1.3-$1.4 billion and adjusted EBITDA of $2.27-$2.31 billion, and said it is advancing the planned EMEA packaging separation.

Analysis

The key issue is earnings quality, not the non-cash EMEA impairment: North American improvement also benefited from a full quarter of NORPAC, lower outage expense and the non-repeat of Riverdale conversion costs. Softer volumes helped reduce costs, while recovered-fiber, energy and freight pressures remain. That makes the Q4 step-up in North America guidance a test of repeatable mill productivity and pricing, not just a headline beat. If customers resist box-price increases while input costs stay elevated, margins could disappoint even with stable sales.

EMEA’s impairment is a reset of carrying value, not a cash drain; however, ending segment guidance ahead of separation increases information risk and makes the November 3 DS Smith Capital Markets Day important. A credible standalone outlook could reduce the separation discount; weak detail or a more cautious outlook would raise concern that value is being transferred out of IP without adequate visibility. Competitors may benefit if EMEA restructuring or pricing gaps weaken customer service or supply, but there is no evidence here of material share shifts.

Near term, the market may look through the impairment and focus on adjusted earnings and Q4 targets. Over 1–3 months, cash conversion and delivery against the North American guide matter more: quarterly free cash flow was negative, and higher capex limits the inference investors should draw from EBITDA. Over 6–18 months, separation execution and standalone EMEA economics drive the valuation case. The constructive view is that the impairment clears a legacy valuation issue and North America is structurally improving; the counterpoint is that operational gains include non-repeatable and acquisition-related benefits. Falsifiers: a Q4 North American operating-profit miss, weaker pricing/volume commentary, or an EMEA outlook at Capital Markets Day that undermines separation economics.

Key Decisions for Investors

• Keep IP neutral-to-underweight into the November 3 EMEA Capital Markets Day rather than buying the adjusted-earnings rebound outright. Reassess after the event; add only if management provides a credible standalone EMEA outlook and North America remains on track for its Q4 operating-profit range.
• For an existing IP position, treat the Q4 North America targets as the near-term execution hurdle. Reduce exposure if mill productivity or pricing fails to offset recovered-fiber, energy and freight costs; do not use the goodwill impairment alone as a sell signal.
• Watch the November 4 Form 10-Q and subsequent updates for capex, working-capital movements, debt maturities/refinancing and cash generation. Persistent negative free cash flow alongside weaker operating performance would challenge the thesis that EBITDA improvement is translating into balance-sheet flexibility.
• Potential upside entry: add only after confirmation that North American improvement persists beyond acquisition timing and temporary cost benefits, and that EMEA separation disclosures reduce rather than increase valuation uncertainty.